New Nanoparticle Vaccine Adjuvant to Autoimmune Disorders

Yet another gaming of the inherent inadequacy of vaccinations is sure to result in ever more of the autoimmune disorders plaguing modern society. New research is focused on a bioengineered nanoparticle adjuvant that’s copies a normal part of the autoimmune system.

The New Adjuvant
Published in the journal Nature, “Synthetic mast-cell granules as adjuvants to promote and polarize immunity in lymph nodes” discusses the use of a new adjuvant that contains an inflammation booster called tumor necrosis factor (TNF, sometimes notated as TNF-α), which triggers inflammation. These particles can travel to the lymph nodes and initiate the development of antibodies. Interestingly, the researchers do not claim to prevent infections by using TNF as an adjuvant. Instead, they say that the mice used in trials were better able to fight infections.

The researchers had observed that mast cells, immune system cells found in the skin, use nano-sized granules to communicate with lymph nodes for the production of antibodies. So, they set out to duplicate the process. As researcher Ashley L. St. John stated:

Our strategy is unique because we have based our bioengineered particles on those naturally produced by mast cells, which effectively solve the same problem we are trying to solve of combating infection.

These bioengineered particles consist of a carbohydrate bound to TNF. Apparently, they can carry or drag the antigen injected with them to a lymph node, where antibodies are made. This biologically active adjuvant results in a much stronger immune response than that triggered by other adjuvants.

What the authors don’t consider is whether these engineered bits of encapsulated TNF might also drag things other than the intended antigen to lymph nodes, thus creating even worse autoimmune diseases than already occurring as the result of existing vaccine adjuvants. There’s no indication that the researchers have any intention of investigating the possibility.

Vaccines using this adjuvant are expected soon, because the FDA has already approved all the ingredients and all the immune system factors used in the adjuvant. In all likelihood, no testing will be required. Once an ingredient is approved for one use, it’s assumed safe for virtually any use—including injections.

Source :

Be the first to comment

Leave a Reply

Your email address will not be published.


18 − one =